Collectively, our findings demonstrated that NEDD9 overexpression associated with genetic abnormalities as well as prognosis might act as a potential biomarker guiding the choice between HSCT and chemotherapy in patients with AML. Here, NEDD9 is linked to acute myeloid leukemia.